Utilizing its proprietary MabIgX technology platform, the company identifies rare, potent antibody-producing B-cells from patients who have successfully overcome an infection to produce mAbs.

Aridis has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP).

Its mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.

The company's pipeline includes six therapies for VAP, HAP, cystic fibrosis, blood stream infections and respiratory syncytial virus infection.